Compare CVS Health Corp (CVS) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs MakeMyTrip Ltd — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while MakeMyTrip Ltd trades at $44.73 (market cap $4.09B). The key difference: CVS Health Corp is far larger — about 27.5× MakeMyTrip Ltd's market cap, and CVS Health Corp pays a 3.03% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and MakeMyTrip Ltd for 12 Days on average.
| CVS | MMYT | |
|---|---|---|
Market Cap | $112.29B | $4.09B |
Volume | 7,763,676 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $92.25 |
52-Week Low | $70.08 | $36.30 |
Typical Hold Time | 83 Days | 12 Days |
Enterprise Value | $174.64B | $4.75B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% with a bearish technical signal. The company shows strong revenue growth to $402.1B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus is overwhelmingly bullish with 85% buy ratings and a $111.20 price target representing 27% upside. Recent news highlights Aetna's 2027 Medicare plan enhancements and quarterly dividend declarations.
CVS presents a compelling value opportunity with attractive valuation metrics (P/E 23.17, P/S 0.27) and strong analyst support. Key risks include reimbursement pressure, regulatory scrutiny from ongoing investigations, and declining net margins. The stock's current technical weakness contrasts with solid fundamentals and positive earnings momentum.
MakeMyTrip (MMYT) trades at $43.53, up 0.28% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported mixed quarterly earnings, with a Q1 2026 beat and Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, but net income margin compressed to 3.23% in 2026. Analyst consensus is strongly bullish with a $77.00 price target, though institutional selling has been noted recently.
The outlook is bifurcated: strong analyst support and a potential Indian listing offer upside, but declining profitability, high P/E ratio, and bearish technicals pose risks. Investors face volatility from operational execution and travel industry cyclicality against a backdrop of Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
